Internal Medicine, Medical Oncology · Saint Louis, MO
NPI
1639332968
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
4921 Parkview Pl, Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO, 63110
Phone (800) 647-2098
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
104,212 services
Medicare patients, 2024
629
Average age 73
Drug cost, 2024
$2.4M
2,073 prescriptions
Company payments, 2025
$68.49
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Peter J Oppelt was code J9299 (injection, nivolumab, 1 mg), 13,740 times for 17 patients. In total Peter J Oppelt billed 104,212 services in 150 codes, and Medicare paid $2.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 13,740 | 17 | $23.52 | $323K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 12,800 | 36 | $42.51 | $544K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,900 | 28 | $0.11 | $729 |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 2,210 | 13 | $0.06 | $132 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,930 | 96 | $0.09 | $176 |
| J0897 Injection, denosumab, 1 mg | Office | 1,620 | 11 | $19.76 | $32K |
| Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 1,420 | 13 | $25.59 | $36K |
| J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 1,270 | 14 | $38.48 | $49K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,010 | 59 | $0.80 | $808 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 640 | 28 | $0.26 | $167 |
| J9190 Injection, fluorouracil, 500 mg | Office | 559 | 22 | $2.37 | $1,325 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 555 | 16 | $3.70 | $2,053 |
| 99214 Office E&M - Established | Office | 533 | 203 | $94.78 | $51K |
| J9206 Injection, irinotecan, 20 mg | Office | 438 | 17 | $1.96 | $860 |
| 96413 Chemotherapy Administration | Office | 364 | 208 | $91.06 | $33K |
By year: 2022 $2.8M for 135,985 services; 2023 $4.2M for 217,834 services; 2024 $2.4M for 104,212 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 49 | 26 | $8.65 | $424 |
Medicare prescription drug claims, 2024
In 2024, the drug Peter J Oppelt prescribed most often to Medicare patients was Prednisone, with 226 prescriptions and refills. In total Peter J Oppelt wrote 2,073 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 226 | 237 | 63 | $875 |
| Oxycodone Hcl Generic | 218 | 218 | 61 | $4,893 |
| Levothyroxine Sodium Generic | 201 | 333 | 48 | $1,083 |
| Prochlorperazine Maleate Generic | 169 | 169 | 106 | $4,283 |
| Ondansetron Hcl Generic | 115 | 118 | 70 | $985 |
| Dexamethasone Generic | 94 | 94 | 59 | $1,545 |
| Gabapentin Generic | 89 | 106 | 25 | $994 |
| Abiraterone Acetate Generic | 67 | 67 | 14 | $12K |
| Lidocaine Hcl Viscous Lidocaine Hcl | 65 | 65 | 22 | $1,430 |
| Potassium Chloride Generic | 48 | 58 | 19 | $873 |
| Morphine Sulfate Er Morphine Sulfate | 36 | 36 | 14 | $831 |
| Xarelto Rivaroxaban | 32 | 39 | Under 11 | $22K |
| Fentanyl Generic | 29 | 29 | Under 11 | $2,700 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 26 | 30 | 15 | $46.41 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 26 | 26 | Under 11 | $3,253 |
Brand drugs: 356 claims; generic drugs: 1,717 claims; opioid claims: 371.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Peter J Oppelt $68.49 ($68.49 in general payments such as food, travel and fees) from 2 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $68.49.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 1 | $68.49 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.